Yoji Yamashita

Natori-shi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.

Journal: Cancer science

Published: May 06, 2026

Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma.

Consolidation reduced-dose whole-brain radiation therapy with response-adapted boost in older patients with newly diagnosed primary central nervous system lymphoma.

Journal: Journal of neuro-oncology

Published: December 27, 2025

The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models.

The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models.

Journal: The Journal of biological chemistry

Published: October 10, 2025

Primary Leptomeningeal Lymphoma Presenting As Rapidly Progressive Hydrocephalus: Diagnosis and Symptom Relief Through Endoscopic Ependymal Biopsy and Third Ventriculostomy.

Primary Leptomeningeal Lymphoma Presenting As Rapidly Progressive Hydrocephalus: Diagnosis and Symptom Relief Through Endoscopic Ependymal Biopsy and Third Ventriculostomy.

Journal: Cureus

Published: February 05, 2025

FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells.

FDX2, an iron-sulfur cluster assembly factor, is essential to prevent cellular senescence, apoptosis or ferroptosis of ovarian cancer cells.

Journal: The Journal of biological chemistry

Published: April 17, 2024

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Journal: Nature communications

Published: April 18, 2023

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group.

Journal: Brain tumor pathology

Published: November 09, 2021

PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features.

PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features.

Journal: Cancer science

Published: October 14, 2021

The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.

The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group.

Journal: International journal of clinical oncology

Published: April 14, 2021

Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.

Ppp6c deficiency accelerates K-rasG12D -induced tongue carcinogenesis.

Journal: Cancer medicine

Published: December 07, 2020

Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.

Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.

Journal: Cancer science

Published: October 16, 2020

Phase I trial of convection-enhanced delivery of nimustine hydrochloride (ACNU) for brainstem recurrent glioma.

Phase I trial of convection-enhanced delivery of nimustine hydrochloride (ACNU) for brainstem recurrent glioma.

Journal: Neuro-oncology advances

Published: July 10, 2020

Showing 1-12 of 33

Last Updated: 09/26/2026